Case Series or Uncontrolled Clinical Study?

To the Editor—We read with interest the article by Ramsay and Luterman and accompanying editorial discussing the use of high-dose dexmedetomidine as a single-agent intravenous anesthetic. We have several concerns, both with the technique described and the journal’s editorial position.

As to the case series itself, we wonder what was the basis for the clinical choice to use doses of dexmedetomidine at more than 7 to 50 times the recommended dose range of 0.2–0.7 µg·kg⁻¹·h⁻¹ as the sole anesthetic. Ebert et al.’s work with volunteers was extremely limited and in no way established dexmedetomidine as a safe single-agent anesthetic. Indeed, doses of dexmedetomidine lower than those in the case series have been recently reported as “accidental overdose” and are accompanied by guidelines for the management of same. Although Ramsay and Luterman’s cases imply that the doses were increased when the patients could not tolerate the procedures at lower dose levels, there is no mention of the initial anesthetic plan. Did the authors undertake the anesthetics with the expectation of using dexmedetomidine at massive, unstudied doses? Given the properties of dexmedetomidine at its usual clinical dose range, it is unlikely that patients would be able to tolerate the procedures described without either supplementation or rapid escalation to massive doses, as actually occurred. We find no convincing evidence in the literature to believe that their course of action could be chosen with confidence in its safety and efficacy. The intraoperative management of the cases is also unusual. We fail to understand their need to avoid the use of supplemental oxygen except when absolutely necessary. The argument regarding electrocautery is unconvincing. It is almost as if the decreased margin of safety is used as a demonstration of dexmedetomidine’s properties with respect to maintenance of ventilation. In the two cases that did not receive supplemental oxygen, were the patients subsequently placed on oxygen in the postanesthesia care unit? Finally, we question the assertion that recovery time in these patients was not significantly prolonged when compared with many conventional anesthetic techniques. A recovery time and postanesthesia care unit stay of 2 to 3 h is considered by many to be significantly prolonged and is not a desirable side effect.

We are therefore concerned that Anesthesiology tacitly endorses this anesthetic technique by calling it “another arrow for the clinician’s quiver” in the accompanying editorial. On the basis of Ebert et al.’s two volunteers and the three cases described by Ramsay and Luterman, are we to assume that this is now an acceptable practice? Certainly, we all daily administer many medications “off-label” in a safe and reasonable manner. There comes a point, however, when the off-label use of a drug crosses the line of “reasonable” and becomes a deviation from the standard of care. Until properly controlled, Institutional Review Board drug crosses the line of “reasonable” and becomes a deviation from the standard of care. Until properly controlled, Institutional Review Board

Finally, the lack of complete disclosure of conflicts of interest on Dr. Ebert’s part is disturbing. The annotation states, “Dr. Ebert is not supported by, nor maintains any financial interest in, any commercial activity that may be associated with the topic of this editorial.” This may be true only in the strictest and most limited interpretation of the statement, but ignores Dr. Ebert’s long and close association with Abbott Laboratories (Abbott Park, IL) and previous substantial financial support and honoraria. In fact, the study cited by Ebert in the editorial, examining high-dose dexmedetomidine in volunteers, was itself supported by a grant from Abbott Laboratories. At best, this is disingenuous. The casual reader of the journal should be fully aware that an unproven anesthetic technique, utilizing an expensive drug manufactured by Hospira, Inc. (Lake Forest, IL), a wholly-owned spin-off company of Abbott Laboratories, is advocated by an Abbott-funded investigator and is trumpeted by editorial writers with a long history of close association and support from Abbott Laboratories. It is difficult to understand how one can consider this an objective review of scientific data.

George Mychaskiw, II, D.O.,* Ahmed E. Badr, M.D. * University of Mississippi School of Medicine, Jackson, Mississippi. mychaskiw@anesthesia.umsmed.edu

References

1. Ramsay MAE, Luterman DL: Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 2004; 101:787–90
2. Ebert T, Maze M: Dexmedetomidine: Another arrow for the clinician’s quiver. Anesthesiology 2004; 101:568–70

(Accepted for publication January 18, 2005.)

In Reply—I believe Dr. Mychaskiw and Dr. Badr indicate four areas of concern in their Letter to the Editor. The first relates to the clinical choice of using extremely high doses of dexmedetomidine, the second refers to case management and oxygen therapy, the third is the perception that the journal endorses the technique of “off-label” use of dexmedetomidine, and the fourth has to do with my conflict of interest disclosure. I believe the first two concerns are questions about the editorial review process. Clearly, expert reviewers provided sufficient enthusiasm to have the case reports published. I was not involved in the review and cannot comment except on one area of concern; my personal belief is oxygen is generally good for patients, even during spontaneous ventilation.

I do wish to comment on the third issue of the journal’s perceived “endorsement” of the “off-label” use of dexmedetomidine in the clinical care of several difficult cases. Case reports are meant to “draw attention to important and novel clinical situations, treatments, and
In Reply—I certainly understand the concerns of Mychaskiw and Badr regarding the case reports in which we described the administration of high off label doses of dexmedetomidine to patients with critical airway related problems. This was not certainly not a recommendation for those practitioners inexperienced in the use of dexmedetomidine to attempt this anesthetic technique. The administration of these doses of dexmedetomidine was only performed after extensive experience with the use of this drug over a long period of time and in carefully monitored patients. This technique was utilized in scenarios where current anesthetic methods have significant drawbacks. I described the use of high doses of dexmedetomidine in three patients where current anesthetic techniques presented a significant risk/benefit challenge.

There are a number of published accounts on the administration of high doses of dexmedetomidine. Venn et al. have found that doses of up to 2.5 μg·kg⁻¹·h⁻¹ are necessary to control agitation in critically ill medical intensive care unit patients. There were no reports of adverse hemodynamic or other unwanted events. Jordan et al. have published a review of a number of cases where inadvertent overdoses of dexmedetomidine have been administered. These included patients who had dexmedetomidine administered in doses of up to 20 μg·kg⁻¹·h⁻¹. The only adverse effects noted were extreme sedation and loss of airway control in some of the patients, a clinical scenario very similar to my report of patient #2, who received a maximum of 10 μg·kg⁻¹·h⁻¹ and who required a ‘chin-lift’ during the procedure. The infusion rates in my case reports were very carefully controlled and could have been reduced or stopped at any time if any concerns were raised. The hemodynamic changes associated with the administration of dexmedetomidine have been well described and may be ameliorated effectively if the patient is closely monitored and early intervention is made.

This was not a clinical research project but individual patient care given in the patients’ best interest by physicians well experienced in the use of dexmedetomidine; therefore Institutional Review Board permission was not necessary nor was written patient consent. However, the anesthetic technique was discussed in detail with the patients before the procedure. The administration of an approved drug in a way that is not approved by the Food and Drug Administration labeling is lengthy. With each unapproved use came case reports followed by controversy (e.g., letters to editors), followed by controlled studies and ultimately accepted practice when the risk/benefit ratio was proven despite package labeling. Finally, Drs. Mychaskiw and Badr express concern with my attestation that I maintain no financial interest or commercial activity in the topic of our editorial and further perceive that I have received substantial financial support and honoraria from Abbott Laboratories (Abbott Park, IL). Perhaps a careful review of my income statements would have eliminated their adjective ‘substantial.’ Importantly, Hospira Inc. (Lake Forest, IL) owns and markets dexmedetomidine, and they claim no financial relationship to Abbott Laboratories and are listed as a separate company on the New York Stock Exchange. I have not received research funding from Hospira Inc. and do not speak on their behalf. Previously, Abbott Laboratories had marketed dexmedetomidine; my last support from them for a dexmedetomidine study was in 1999. The volunteer studies I refer to in our editorial were funded in the early 1990s. Based on the lack of support for studies with dexmedetomidine for 5 yr and the absence of speaking on this topic on behalf of Hospira Inc. I stand by the strict interpretation of my attestation at the time of the publication of our editorial.

Thomas J. Ebert, M.D., Ph.D., Medical College of Wisconsin and Zablocki VA Medical Center, Milwaukee, Wisconsin. tjebert@mcw.edu

Reference

1. Ebert T, Maze M. Dexmedetomidine: Another arrow for the clinician’s quiver. Anesthesiology 2004; 101:568–70

(Accepted for publication January 18, 2005.)

© 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Anesthesiology 2005, 102:1067–8
in the last sentence of the editorial did they offer the suggestion that dexmedetomidine may have a place in the management of the difficult airway. They recommended further comparative studies to establish the clinical role of dexmedetomidine in difficult airway algorithms. I certainly agree that three case reports are not even enough data to claim an "outcomes" clinical trial; these reports were just observations. However, I am collecting more case reports to add to my initial database. I am also involved in a multicenter prospective clinical trial that is including the use of higher doses of dexmedetomidine than currently on the label and administering them for longer periods of time.

I wholeheartedly support the notion of evidence-based medicine following rigorous randomized controlled clinical trials, but the low incidence of the types of cases we reported will make this difficult to achieve in this patient population.

The "off-label" use of drugs is not unusual in the practice of anesthesiology, especially in some of our more sensitive patient groups such as the pediatric population. I agree with Mychaskiw and Badr that the use of "off-label" drugs needs to be done with extreme caution and is only justified when current therapies are less than optimal.

We thank Drs. Mychaskiw and Badr for raising a cautionary note about the use of these high doses of dexmedetomidine and we certainly emphasize that this should only be done by those practitioners with extensive experience with this drug in well-controlled circumstances and where current technologies are less than ideal. However, as our experience with dexmedetomidine increases, its role in the management of the difficult airway may well become "Another Arrow in the Clinician’s Quiver!".

Michael A. E. Ramsay, M.D., F.R.C.A., Baylor University Medical Center, Dallas, Texas. docram@baylorhealth.edu

References

1. Ramsey MAE, Luterman DL: Dexmedetomidine as a total intravenous agent. ANESTHESIOLOGY 2004; 101:787–90
4. Ebert T, Maze M: Dexmedetomidine: Another arrow for the clinician's quiver. ANESTHESIOLOGY 2004; 101:568–570

(Accepted for publication January 18, 2005.)

To the Editor.—In the article by Johnson et al. and in the follow-up editorial by Shafer, the sensitivity of pigs to propofol after severe hemorrhage is described. In the editorial, the "take-home message" is that propofol is a poor choice for induction. My supplementary "take-home" message is that a monitor of anesthetic depth, such as the Bispectral Index, should be used for all critically ill patients. If a dose of propofol drives the Bispectral Index to 0 (isoelectricity), the patient is probably too deeply anesthetized. Certainly, it is possible that the Bispectral Index is not accurate during shock, i.e., a decrease in Bispectral Index score might not necessarily represent a change in depth of anesthesia. In a case report of a patient who underwent elective abdominal aortic aneurysm repair with total intravenous anesthesia, the Bispectral Index score decreased shortly after the aortic clamp was released; 10 min later other monitored variables suggested clinical deterioration. Although no study has formally analyzed the relationship of Bispectral Index to shock, there are electroencephalographic changes during shock. In awake animal studies of controlled hemorrhagic shock, electroencephalography frequency slows and amplitude increases; the electroencephalograph is flat when blood pressure is inadequate to support respiration. It is not always clear how much anesthesia critically ill patients need. In such situations, I use a depth of anesthesia monitor, use much less anesthesia than I would otherwise have planned to use, and I believe that I also have an easier job of managing blood pressure.

J. Lance Lichtor, M.D., University of Iowa, Iowa City, Iowa. lance-lichtor@uiowa.edu

References


(Accepted for publication January 19, 2005.)

To the Editor.—It has been reported that hemorrhagic shock altered pharmacodynamics of propofol: the potency of propofol increased during hemorrhagic shock. A proposed explanation for this increase of propofol potency is that hemorrhagic shock leads to an increase in circulating beta endorphins. Recent work by Depaepe et al., however, has revealed that endorphin antagonism with naloxone does not influence end-organ sensitivity during hemorrhagic shock in the rat. Other potential sources of increased end-organ sensitivity to propofol is the increase of unbound propofol; this can be achieved through competitive displacement interactions with other drugs or endogenous substances or decreases in the level of proteins.

It is now widely accepted that the pharmacological effects of a drug are elicited by the unbound fraction in the blood. Only those drug molecules that are not bound to plasma protein are able to pass through blood vessels and reach their target sites within the tissue. Therefore, changes in the protein-binding characteristics of a drug may alter its pharmacological potency and pharmacokinetics.

For drugs that are restrictively cleared, regardless of route of admin-

In Reply—We thank Drs. Lichtor and Takizawa et al. for their interest in our study and thought-provoking observations. Dr. Lichtor points out that in settings of hypotensive extremis from blood loss i) perfusion to the brain can be compromised to the point of significantly altering electrical activity in the brain and ii) delivering an anesthetic that results in brain isoelectricity is clearly excessive. It is interesting to note that in our experimental protocol, we performed a series of pilot studies directed at characterizing the impact of our hemorrhage and resuscitation protocol on a processed measure of brain electrical activity, the Bispectral Index score, in the presence of isoflurane. Although hemorrhage was severe (42 ml/kg) and resuscitation protocol was altered following blood loss and resuscitation or how drug distribution and clearance were altered by hemorrhagic shock and resuscitation with crystalloid to near-baseline hemodynamics, the pharmacologic behavior of propofol was still altered when compared with controls. We concluded that hemorrhagic shock followed by resuscitation with lactated Ringer’s solution nearly restored the pharmacokinetic profile of propofol to a pre-hemorrhage state, but that resuscitation did not reverse the pharmacodynamic changes.

From a pharmacokinetic analysis standpoint, our work was primarily observational. We measured plasma propofol levels and estimated volumes and clearances using compartmental models and used these estimates to make comparisons between study groups. We did not make measurements that would allow us to discover how drug distribution and clearance were altered by hemorrhagic shock and resuscitation. For example, we did not measure or estimate i) plasma protein content, ii) propofol-plasma protein binding, or iii) unbound propofol levels throughout our experimental protocol. Furthermore, we did not measure how the initial distribution and subsequent redistribution of propofol was altered following blood loss and resuscitation or how altered plasma pH levels may have impacted unbound propofol availability. Finally, we did not explore to what extent the clearance of unbound propofol by metabolic organs would be compromised by our experimental protocol (e.g., a comparison of hepatic extraction ratios for propofol between control and bled-resuscitated animals). As suggested by Dr. Takizawa et al., what we reported as an increase in end-organ sensitivity to propofol may be, at least in part, attributable to an unrecognized increase in unbound propofol. Thus our reported leftward shift in the C₅₀ of propofol may represent an undetected pharmacokinetic difference between groups. Although the measured plasma propofol levels were comparable between the control and hemorrhage-resuscitation groups, the amount of unbound propofol available to exert a pharmacologic effect may have been increased. After removing more than 50% of the estimated blood volume and accompanying hemorrhage—especially followed by crystalloid resuscitation.

Daisuke Takizawa, M.D.*, Eri Sato, M.D., Dai Kurosaki, Ph.D., Haruhiko Hiraoka, Ph.D., Ryuya Horii, Ph.D., Fumio Goto, Ph.D.* Gunma University, Graduate School of Medicine, Maebashi, Japan. d-takiza@bfo.so-net.ne.jp

References


(Accepted for publication January 19, 2005.)
Replacing it with crystalloid, plasma protein content was most likely decreased. Furthermore, alterations in organ blood flow (as manifest by a change in systemic vascular resistance), capillary wall integrity, and plasma pH may have influenced the levels of unbound propofol.

To the Editor—We report the case of a 68-yr-old obese male patient that was admitted to our university hospital for scheduled elective left carotid endarterectomy under regional anesthesia. Past medical history was significant, with controlled ischemic (four coronary artery bypass grafts at the age of 56 yr) and hypertensive cardiopathy and sleep apnea syndrome balanced with nocturnal ventilation support. Preoperative physical examination detected no abnormality. The patient received a deep cervical plexus block using a single-injection (15 ml 0.5% bupivacaine and 15 ml 2% lidocaine) nerve stimulator-assisted technique. The patient developed respiratory distress associated with bilateral diaphragm paralysis symptoms 15 min after the block was placed. Facemask noninvasive titrated inspiratory pressure-support ventilation resulted in normal breathing pattern and oxygen parameters. After an uneventful surgical procedure the patient was transferred to the ward 2 h after postanesthesia care unit admission. Postoperative ambulatory arterial blood gas analysis and pulmonary functional tests were considered subnormal but phrenic conduction measurements confirmed severe right phrenic nerve conduction alteration.

In this report the patient experienced acute ventilatory failure probably attributable to bilateral diaphragm weakness. Epidural or subarachnoid injection might have promoted similar clinical features. However, the deep cervical plexus block we performed remained strictly ipsilateral to the puncture side. The block concerned left C2-C4 sensory dermatomes but preserved distal motor function of the arm. Then, we believe that the spread of deep cervical plexus block promoted a left phrenic block, resulting in ventilatory failure because of preexisting contralateral phrenic damage. Usually, extension of the block to the phrenic nerve is common during cervical blocks but without significant clinical problems, even in patients with preexisting lung disease. In the present case, unrecognized coronary artery bypass graft-induced right phrenic nerve damage was revealed by the extension of left deep cervical plexus block.

Because up to 10% of cardiac surgery patients may suffer from postoperative electrophysiological abnormal phrenic nerve conduction, we recommend anesthesiologists performing cervical blocks in postcardiac surgery patients remain vigilant attending the patient, with the capacity to supply ventilatory failure.

Gilles D'Honneur, M.D.,* Cyrus Motamed, M.D., Loïc Tual, M.D., Xavier Combes, M.D., * University of Henin Mondor, Creteil Cedex, France. gilles.dhonneur@jvr.ap-hop-paris.fr

References

Support was provided solely from institutional and/or departmental sources.

To the Editor—Recall during general anesthesia has been reported to occur in approximately 1 to 2 per 1000 anesthetic procedures. Most providers are familiar with press reports and litigations by patients to recover damages as a result of recall and suffering while under general anesthesia. I would like to report a phenomenon which I have observed to be occurring more frequently in my practice.

During my preoperative visit, I commonly ask the patient about previous anesthetic exposures. Lately, several patients have stated that they remember most if not all of their last anesthetic. When asked what type of procedure they had that they recall so well, they have invariably replied, colonoscopy, cataract, cardiac catheterization, or similar procedures. When I question this recall event further, it is clear that the procedure they recall was done under sedation and not general anesthesia. Indeed, all of the patients I have interviewed so far who have had other procedures that required general anesthesia, e.g., cholecystectomy, were able to discern the difference in the depth of anesthesia and had no recall of the more invasive procedure. A brief explanation that sedation for endoscopy and other procedures does not reliably ablate recall has been accepted by all patients and to date has eased apprehension that if the current procedure requires a general anesthetic, they will most likely not have any recall or intraoperative awareness.

I get the impression that many patients undergoing endoscopy, catheterization, cataract extraction, and many other procedures that utilize conscious sedation or even moderate sedation are being told they will not remember the procedure. I think it will serve us well to remind our colleagues in the endoscopy suites and the catheterization labs that such is not the case. In addition, we practitioners of anesthesia should not tell patients undergoing spinal, epidural, regional, or monitored anesthetic care that the sedation we may provide will ablate all intraoperative awareness and recall.

The general public has difficulty distinguishing between different levels of sedation and general anesthesia; in fact, this concept is not clearly defined within our own specialty. Caution needs to be exercised when discussing matters of recall and awareness with patients.

Support was provided solely from institutional and/or departmental sources.
First, find out if they truly had a general anesthetic. Second, do not make assurances of memory ablation if you do not plan a general anesthetic and even then be careful what you promise. Third, talk with your colleagues in the endoscopy and catheterization laboratories. I think they are making well-intentioned assurances of memory ablation and are unaware of how often they fail to provide the amnesia they wish to give.

Harold W. Collier, M.D., University of Kansas School of Medicine, Wichita, Kansas. hwcollier@hotmail.com

References


(Accepted for publication January 7, 2005.)